4Moving Biotech announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate's phase 2b clinical trial.  

"With their expertise in clinical study design and regulatory affairs, this high-level scientific advisory board will greatly contribute to the future success of 4P004, reinforcing our pioneering position in developing advanced therapeutic solutions." Concluded Revital Rattenbach, Chairwoman of 4Moving Biotech.

For more information, please refer to the official press release linked here.

‍

‍